Expanded access to addiction treatment and the overdose-reversal med naloxone likely prompted a 37% reduction in OD deaths ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company’s President ...

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.

And if you do have any respiratory symptoms, it goes without saying that you should keep your distance from vulnerable people ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage ...

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

The North Carolina Department of Health and Human Services is reporting the first flu-related death of the 2024-25 flu season. An adult in the Charlotte metropolitan area died due to ...

In some good news for women battling locally advanced cervical cancer, new research shows that adding six weeks of ...

MOBILE, Ala. ( WALA) - At USA Health Children’s & Women’s Hospital, doctors are seeing a rise in pediatric RSV cases. Dr.